NOTCH3

Across TCGA pan-cancer cohorts, NOTCH3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NOTCH3 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NOTCH3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated NOTCH3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where NOTCH3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.173	0.483	<.001	57	view →
CCRCC	DFS	Tertile	All	0.571	0.880	.002	40	view →
LUAD	OS	Tertile	III,IV	0.329	1.000	.016	4	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.851	.024	2	view →
GBM	OS	Median	All	0.450	0.590	.042	1	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

NOTCH3–PDAC (DFS)

Open the PDAC breakdown →